# Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

> **NCT02203851** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 110 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Risankizumab

## Key facts

- **NCT ID:** NCT02203851
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-20
- **Primary completion:** 2018-09-04
- **Final completion:** 2018-09-04
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2019-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203851, "Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02203851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*